MediGene's RhuDex to undergo further safety tests
This article was originally published in Scrip
Executive Summary
MediGene's rheumatoid arthritis candidate RhuDex will be examined in further laboratory tests to determine potential detrimental interactions between RhuDex and arteriosclerotic blood vessels. The studies are expected to be conducted in the first half of 2009 and will be a prerequisite for the further clinical development of the product.